Antibiotics for Emerging Pathogens

Abstract

Antibiotic-resistant strains of pathogenic bacteria are increasingly prevalent in hospitals and the community. New antibiotics are needed to combat these bacterial pathogens, but progress in developing them has been slow. Historically, most antibiotics have come from a small set of molecular scaffolds whose functional lifetimes have been extended by generations of synthetic tailoring. The emergence of multidrug resistance among the latest generation of pathogens suggests that the discovery of new scaffolds should be a priority. Promising approaches to scaffold discovery are emerging; they include mining underexplored microbial niches for natural products, designing screens that avoid rediscovering old scaffolds, and repurposing libraries of synthetic molecules for use as antibiotics.

Streptomyces venezuelae TX‐TL – a next generation cell‐free synthetic biology tool

“…Streptomyces belongs to the high G+C (%) Actinomycetes soil bacteria and represents the leading source of natural antibiotics such as streptomycin and tetracycline [1]. Recently, Streptomyces venezuelae, the chloramphenicol producer, has been adopted by synthetic biology for its use in metabolic engineering [2], since it is relatively well characterized, has strong promoter tools and genome engineering plasmids for integration [3][4][5].…”

Total Synthesis of Disciformycin A and B: Unusually Exigent Targets of Biological Significance

“…[1] Therefore the search for new activep rinciples with different modes of action is warranted, if not even vital in the longer run. [2,3] It is against this backdropt hat the recent reports on the myxobacterialm etabolites of the disciformycina nd gulmirecin families must be seen (Figure 1). [4][5][6][7] These compounds exhibit considerable activity against Gram-positiveb acteria, including several methicillin-or vancomycin-resistant Staphyllococcus aureus strains;m ost notably,t hey seem to address an as yet unknown biological targeta nd hence likelyp rovide new opportunities in the quest for antibiotics devoid of cross-resistance with approved drugs.…”

A study of in vitro antibacterial activity of lanthanides complexes with a tetradentate Schiff base ligand

“…To this solution, 10 6 were added in drop wise manner. The reaction mixture was stirred for 2 h at room temperature.…”

“…To overcome the threat of antibiotic resistant bacteria, drug companies are in the process of development of new antibiotics and some have already reached clinical trials [6] . Many of these are semi-synthetic modifications of already existing antibiotics, including new beta-lactams, macrolides glycopeptides, quinolones and modifications of vancomycin.…”